Moderna Inc (MRNA) Posted -43.84% Profit Margin Last Year—Can It Hold Up?

Bernstein has recently initiated Moderna Inc (MRNA) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on September 13, 2024, Oppenheimer had reduced the stock from a Outperform to Perform. JP Morgan also reduced Underweight rating with a price target of $70. Additionally, Jefferies reduced Hold rating on September […]

Moderna Inc (MRNA) Stock: Surpassing Expectations in the Market?

Bernstein has recently initiated Moderna Inc (MRNA) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on September 13, 2024, Oppenheimer had reduced the stock from a Outperform to Perform. JP Morgan also reduced Underweight rating with a price target of $70. Additionally, Jefferies reduced Hold rating on September […]

Moderna Inc (MRNA) Stock: More Strategic Than Meets the Eye

Bernstein has recently initiated Moderna Inc (MRNA) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on September 13, 2024, Oppenheimer had reduced the stock from a Outperform to Perform. JP Morgan also reduced Underweight rating with a price target of $70. Additionally, Jefferies reduced Hold rating on September […]

Why Did Moderna Inc (MRNA) Stock See -34.77% Plunge in the Last 90 Days?

Bernstein has recently initiated Moderna Inc (MRNA) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on September 13, 2024, Oppenheimer had reduced the stock from a Outperform to Perform. JP Morgan also reduced Underweight rating with a price target of $70. Additionally, Jefferies reduced Hold rating on September […]

Moderna Inc’s Stock Drama: Could This Be a Game-Changer for MRNA Investors?

Bernstein has recently initiated Moderna Inc (MRNA) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on September 13, 2024, Oppenheimer had reduced the stock from a Outperform to Perform. JP Morgan also reduced Underweight rating with a price target of $70. Additionally, Jefferies reduced Hold rating on September […]

Moderna Inc (MRNA) Stock: Beyond the Surface of Its Performance?

Bernstein has recently initiated Moderna Inc (MRNA) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on September 13, 2024, Oppenheimer had reduced the stock from a Outperform to Perform. JP Morgan also reduced Underweight rating with a price target of $70. Additionally, Jefferies reduced Hold rating on September […]

MRNA Stock Fluctuations: The Real Story

Bernstein has recently initiated Moderna Inc (MRNA) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on September 13, 2024, Oppenheimer had reduced the stock from a Outperform to Perform. JP Morgan also reduced Underweight rating with a price target of $70. Additionally, Jefferies reduced Hold rating on September […]

Why Did Bernstein Give Moderna Inc (MRNA) Stock Mkt Perform Rating?

Bernstein has recently initiated Moderna Inc (MRNA) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on September 13, 2024, Oppenheimer had reduced the stock from a Outperform to Perform. JP Morgan also reduced Underweight rating with a price target of $70. Additionally, Jefferies reduced Hold rating on September […]

Why Moderna Inc (MRNA) Stock is Currently -10.18% Off from Its 20-Day SMA?

Bernstein has recently initiated Moderna Inc (MRNA) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on September 13, 2024, Oppenheimer had reduced the stock from a Outperform to Perform. JP Morgan also reduced Underweight rating with a price target of $70. Additionally, Jefferies reduced Hold rating on September […]

Why Did Moderna Inc (MRNA) Stock Rise 0.80% to $58.86?

Oppenheimer has recently reduced Moderna Inc (MRNA) stock to Perform rating, as announced on September 13, 2024, according to Finviz. Earlier, on September 13, 2024, JP Morgan had reduced the stock from a Neutral to Underweight, setting a price target of $70 for MRNA stock. Jefferies also reduced Hold rating with a price target of […]